The connection between AR expression and cancer cell sensitivity to AA, suggested by our study and that of Wang et al. [80], could be pursued to develop novel combination therapies for AR-dependent tumors, including certain sub-types of triple negative breast cancer, and the early stage and castration-resistant phase of prostate cancer. This evidence concerns the gene AR and cancer.